This publication provides guidance on the management of adult patients with myelodysplastic syndrome. It covers essential diagnostic tests and management of low and high risk disease. The guidance also makes recommendations for supportive care including the use of erythropoietin stimulating agents and iron chelation. The relative merits of allogeneic haematopoietic stem cell transplantation are also discussed.

Note: The MDS guideline committee would like to correct an error on page 506 regarding cytogenetic analysis in this guidelines article.  it should read 'cytogenetic analysis should be performed on at least 20 metaphases and should be reported in accordance with the International System Recommendations.  

Declaration of Interests

The BSH paid the expenses incurred during the writing of this guidance. None of the authors had conflicts of interest to declare. All authors have made a declaration of interests to the BSH and Task Force Chairs which may be viewed on request.